QNR
TW EN

scroll

Go Top

醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 臨床試驗中心Far Eastern Memorial Hospital Clinical Trial Center

  • Total Beds1,329
  • Total Doctors616
  • AddressSouth Building B1, No. 21, Section 2, Nanya S. Road,Banqiao,New Taipei City 220
  • Emailfemh96982@mail.femh.org.tw
Link to Hospital Link to Clinical Trial Center

1. The institution and research team have ample experience in conducting clinical trials for cell therapy.

2. They possess rigorous procedures for executing clinical trials, ensuring the rights and safety of participants.

3. They promote early-stage clinical trials and continuing education in clinical trial practices.

Site Introduction

Clinicl Trial Expertise

Cardiovascular diseases, metabolism, kidney diseases, rheumatology and immunology, tumors (lung cancer, liver cancer, gynecological cancer, etc.), hepatobiliary and gastrointestinal diseases, pulmonary diseases, infectious diseases.

International Accreditation

FERCAP

GCP Inspection/audit

TFDA

What types of clinical trial do you conduct?

Publications

CTC

1

National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. Diabetes Ther 2015 ;6(4):519-530

2

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015 ;38(3):384-93

3

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 2017;19(11):1610-1619

4

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019;393(10184):1937-1947

5

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166

6

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79

7

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7(6):429-441

8

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29

9

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383(15):1425-1435

10

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63

1 2

下一頁

Introduction

About Us History

Taiwan Spotlight

Health Overview Clinical Trial Focus International Accreditations
Clinical Trial Centers TCTC c-IRB
Resources News e-LEARNING Contact Us
All Contents Copyright 2019 Center for Drug Evaluation (CDE),Taiwan/ This website is operated by Center for Drug Evaluation (CDE), Taiwan